No headlines found.
Globe Newswire (Wed, 26-Nov 8:00 AM ET)
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Fri, 14-Nov 8:30 AM ET)
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Globe Newswire (Fri, 17-Oct 9:00 AM ET)
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Globe Newswire (Thu, 9-Oct 8:30 AM ET)
Globe Newswire (Tue, 16-Sep 8:00 AM ET)
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Adial Pharmaceuticals trades on the NASDAQ stock market under the symbol ADIL.
As of December 16, 2025, ADIL stock price was flat at $0.27 with 130,957 million shares trading.
ADIL has a beta of 1.33, meaning it tends to be more sensitive to market movements. ADIL has a correlation of 0.07 to the broad based SPY ETF.
ADIL has a market cap of $7.20 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ADIL traded as high as $15.00 and as low as $.22.
The top ETF exchange traded funds that ADIL belongs to (by Net Assets): VXF.
ADIL has underperformed the market in the last year with a price return of -75.2% while the SPY ETF gained +13.3%. ADIL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.9% and -13.7%, respectively, while the SPY returned +2.8% and -0.4%, respectively.
ADIL support price is $.26 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADIL shares will trade within this expected range on the day.